Scopus BioPharma Inc.: management transactions · United States · SEC (Form 4)

About Scopus BioPharma Inc.

Scopus BioPharma Inc. (ticker: SCPS) is a U.S.-listed biopharmaceutical company traded on NASDAQ in the United States, focused on developing innovative therapies for serious diseases with significant unmet medical needs. The company was incorporated in Delaware in 2017 under the name Project18 Inc. and changed its name to Scopus BioPharma later that year. Its principal executive offices have been identified in New York, with additional operational ties to Israel and, historically, research-related activities associated with Los Angeles. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1772028/000110465920085668/tm2024664d1_partiiandiii.htm?utm_source=openai)) Scopus BioPharma describes itself as an early-stage biotech built around collaboration with leading academic and research institutions. Its publicly described strategic partners have included City of Hope, the NIH, and Hebrew University, reflecting a model that depends on external scientific discovery, translational research, and licensing or partnership structures rather than a fully integrated commercial platform. For equity investors, this makes SCPS a development-stage story where valuation is driven primarily by pipeline progress, intellectual-property strength, and financing capacity. ([scopusbiopharma.com](https://scopusbiopharma.com/about/overview/?utm_source=openai)) In terms of business lines, the company has been centered on oncology and immunotherapy programs. Historical SEC and company materials highlight a lead candidate built around STAT3 targeting, a pathway widely associated with cell growth, immune response, and cancer biology, as well as additional immunotherapy-oriented assets. Scopus also announced the acquisition of Olimmune as part of an effort to expand its immunotherapy pipeline. This suggests a narrow but science-intensive portfolio with potential upside if clinical translation and partnering succeed, but also substantial clinical, regulatory, and funding risk. ([scopusbiopharma.com](https://scopusbiopharma.com/wp-content/uploads/Scopus-BioPharma-Expands-Immunotherapy-Pipeline-with-Acquisition-of-Olimmune-06.30.21-FINAL.pdf?utm_source=openai)) From a competitive standpoint, Scopus BioPharma is a small-cap biotech competing in a crowded field against larger pharmaceutical companies and better-capitalized specialty biotechs. Its differentiation lies in targeting biologically complex mechanisms and in its academic-network approach, but it does not have the scale, diversification, or commercial revenue base of established pharma peers. Public filings describe the company as early-stage and note that it had not generated revenues, which reinforces the speculative nature of the investment case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1772028/000141057823000666/scps-20221231x10k.htm?utm_source=openai)) Geographically, the company’s footprint is primarily U.S.-based, with headquarters in New York and a corporate setup that includes Israeli exposure through subsidiary or collaboration infrastructure. Recent public materials available online emphasize recapitalization, pipeline reshaping, and strategic asset integration more than late-stage commercialization. For investors tracking SEC Form 4 insider transactions, the key takeaway is that Scopus BioPharma remains a high-volatility development story in which insider activity, financing events, and pipeline updates can be particularly important market signals. ([scopusbiopharma.com](https://scopusbiopharma.com/wp-content/uploads/Scopus-BioPharma-Completes-Recapitalization-Designed-to-Enhance-Shareholder-Value-10.18.22-FINAL.pdf?utm_source=openai))